Skip to content

to compare combination of Buprenorphine-naloxone with moxonidine versus clonidine in opioid detoxification

The comparative efficacy of Buprenorphine-naloxone with moxonidine versus Buprenorphine-naloxone with clonidine for short term detoxification in opioid use disorders

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/043760
Enrollment
126
Registered
2022-07-06
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F112- Opioid dependence

Interventions

Intervention1: moxonidine in combination with buprenorphine- naloxone: Assessment tools at baseline, 7 days and 14 days. After 14 days, all the participants will be given oral Naltrexone (25 mg /day)

Sponsors

Govt Medical College Rajindra Hospital Patiala
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient should fulfill the criteria of opioid use disorder as DSM-5. 2. Patient should be in withdrawal state at the time of admission (should fulfill the DSM-5 criteria of opioid withdrawal syndrome). 3. Should be in the age group of 18 to 50 yrs. 4. Patients who will give voluntary informed consent for detoxification.

Exclusion criteria

Exclusion criteria: 1. The patients who are diagnosed with any major physical illness, organic brain disease, epilepsy, schizophrenia, other psychosis or mental retardation will be excluded. 2. Current alcohol abusers or those taking any other drugs along with opioids will also be excluded. 3. Patients whose BP 4. Patients with bradycardia (heart rate 5. Pregnant and breast feeding women are to be excluded. 6. Elderly of age > 60 yrs are excluded. 7. Patients on Beta blockers, Calcium channel blockers, Tricyclic antidepressants, Digitalis that interact adversely with Clonidine.

Design outcomes

Primary

MeasureTime frame
Primary outcome measures will be success of detoxification, therapeutic efficacy on CGI, craving assessment on VAS and withdrawal response on improvement in Clinical Opioid Withdrawal Scale (COWS) and Subjective Opioid Withdrawal Scale (SOWS).Level of motivation will be assessed on SOCRATES-8D scale. Timepoint: Primary outcome measures will be assessed at baseline, at 7 days and at 14 days.

Secondary

MeasureTime frame
safety of the drugsassessed onADR scale, well being on SF ââ?¬â?? 36 scale, retention on Naltrexone treatment and relapse rates in three month follow-up.Timepoint: Three months

Countries

India

Contacts

Public ContactDr Parvarjot Kaur

Government Medical College and Rajindra Hospital ,Patiala

profheadpsy@yahoo.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026